Long-term proton pump inhibitor therapy and risk of hip fracture.
about
Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adultsClinical practice. Gastroesophageal reflux diseaseOpioid analgesics and the risk of fractures in older adults with arthritisDurability of radiofrequency ablation in Barrett's esophagus with dysplasiaOverutilization of proton-pump inhibitors: what the clinician needs to knowProton pump inhibitors and gastritisOverprescribing proton pump inhibitorsEsomeprazole and aspirin fixed combination for the prevention of cardiovascular eventsChronic proton pump inihibitor therapy and calcium metabolism25 Years of Proton Pump Inhibitors: A Comprehensive Review.Recognizing and treating secondary osteoporosisProton pump inhibitors and risk of periampullary cancers--A nested case-control studyConfounding in the association of proton pump inhibitor use with risk of community-acquired pneumoniaEvolution of primary care databases in UK: a scientometric analysis of research outputAssociation between proton pump inhibitors and hepatic encephalopathy: A meta-analysis.Gastroprotective mechanism of Paederia foetida Linn. (Rubiaceae)--a popular edible plant used by the tribal community of North-East India.The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.Cost-effectiveness of chemoprevention with proton pump inhibitors in Barrett's esophagus.Likelihood ratio based tests for longitudinal drug safety data.Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies.Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors.The tell-tale heart: population-based surveillance reveals an association of rofecoxib and celecoxib with myocardial infarctionOsteoporosis piece of multi-morbidity puzzle in geriatric care.Perils and pitfalls of long-term effects of proton pump inhibitors.A Review of the Novel Application and Potential Adverse Effects of Proton Pump Inhibitors.Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.Effects of long-term PPI treatment on producing bowel symptoms and SIBO.Calcium citrate and vitamin D in the treatment of osteoporosis.Efficacy of Albis for the Prevention of Gastric Mucosal Injury Concomitant with the Use of Low-Dose Aspirin: A Prospective, Randomized, Placebo-Controlled Study.Urban versus rural differences in the occurrence of hip fractures in Japan's Kyoto prefecture during 2008-2010: a comparison of femoral neck and trochanteric fracturesCost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.Proton-pump inhibitors use, and risk of acute kidney injury: a meta-analysis of observational studies.Long-term proton pump inhibitor use and gastrointestinal cancerStress fractures in older athletes: a case report and literature reviewPotentially inappropriate prescribing and cost outcomes for older people: a national population study.The Relationship between H. pylori Infection and Osteoporosis in Japan.Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the PROTECT projectEffect of acetylcholinesterase inhibitors on post-surgical complications and mortality following a hip fracture: a cohort study.Atrophic gastritis: a related factor for osteoporosis in elderly women.Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.
P2860
Q24243768-B2118D36-B86C-4C85-AB48-976DD1F685A5Q24596151-85444953-F548-4FA8-9490-30AC4062D41AQ24607425-896C48E2-C2B7-42E3-ABB2-2C36464E8891Q24621075-C1283270-03A0-4116-855A-68FA9252EFDCQ24634086-E8A02A46-F48A-4604-913E-EDCD8ABE67C9Q24655315-E74EDF21-3A56-47AB-82CE-7E25B3A4D285Q24669995-838CCF3B-E4BE-4246-A6E0-9C0AF3734CDEQ26995752-E336490E-6762-4820-8B36-85B77B09E1FCQ27016636-01D2E85A-AD39-494A-B2ED-27B4FA0F71EFQ28070003-935F84FB-70ED-4671-B42D-7A1B4D4A9F1BQ28270738-7CFBC8B0-16C9-4D03-8824-CEADA1A79877Q28385784-F4170609-4C76-4B7B-904D-DAFC632C0572Q28396345-ED3AD905-5939-4C31-8518-F6E018651086Q28552854-00BDDF58-B329-4142-BB88-324534DF156FQ30234653-B910EDC3-8D66-492D-A025-43DD45ACAD7BQ30387731-C20C1698-11A6-40B3-A596-D06EA3FBC12EQ30415171-86FD05E5-AA3A-4030-9498-B4F67D0512EBQ30619561-5ABCAB4C-B435-4ED7-9D9B-C654F69DC8D2Q30830496-F6847974-20CF-47C9-B1C5-4B264FBB4AA9Q30928614-CDE7E837-53DB-46BA-9B51-6BACCD017277Q31157434-FF3BCA3C-3EA1-4F9A-A559-9DF04115BA28Q33297001-5FF00FFB-8293-4EEE-AC49-133924CA7A8FQ33351754-372CA684-C8F5-4D8B-B033-945B2A9B8BA0Q33409626-347E2D28-FE59-401C-A9A1-D0BBE4EA1BE9Q33441225-0CB47726-5A59-44B8-947E-9215EE7041C6Q33445961-780B4628-DC69-4F50-8A99-10E5248CC6A0Q33448825-10002B47-971D-492B-9F52-D0CB890BBD3AQ33449783-3123105E-5172-456A-BCBF-CD0F30919E58Q33583991-13B5D08E-C249-4A54-BCED-BC7807B6B7EAQ33592559-BEF7ABAC-01CB-45AC-9FCF-DA8AEC4E45CCQ33611577-4F4CCDA0-E40C-4CF6-A7CA-3D5D7B3164EBQ33621128-0AE3D72B-B1AC-45A6-8F91-C70EF0732E0EQ33727006-DCDC1CFB-96C9-43C7-A721-0EECBCB1F20CQ33760997-E5F5579E-CBA8-4FBA-9E7C-20CF6200B519Q33795093-CFF40E8F-BBF6-4C4A-9BA6-4E9EA1BF9A99Q33849962-8945D5B7-FF89-4B28-9125-927545B4D605Q33851671-08880832-6CE9-4528-A5EA-9542302A1A48Q33856939-A1BCCB1E-A23F-4E0F-AF8D-56B4C7BCAC65Q33864395-C47FED22-0539-4646-B94E-E098375D313AQ33879548-C135E641-CA24-485D-A5C1-F73049EF1CC8
P2860
Long-term proton pump inhibitor therapy and risk of hip fracture.
description
2006 nî lūn-bûn
@nan
2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Long-term proton pump inhibitor therapy and risk of hip fracture.
@ast
Long-term proton pump inhibitor therapy and risk of hip fracture.
@en
Long-term proton pump inhibitor therapy and risk of hip fracture.
@nl
type
label
Long-term proton pump inhibitor therapy and risk of hip fracture.
@ast
Long-term proton pump inhibitor therapy and risk of hip fracture.
@en
Long-term proton pump inhibitor therapy and risk of hip fracture.
@nl
prefLabel
Long-term proton pump inhibitor therapy and risk of hip fracture.
@ast
Long-term proton pump inhibitor therapy and risk of hip fracture.
@en
Long-term proton pump inhibitor therapy and risk of hip fracture.
@nl
P2093
P356
P1476
Long-term proton pump inhibitor therapy and risk of hip fracture.
@en
P2093
David C Metz
James D Lewis
Solomon Epstein
Yu-Xiao Yang
P304
P356
10.1001/JAMA.296.24.2947
P407
P577
2006-12-01T00:00:00Z